For the full year, the Company reiterated its recently revised top-line guidance of 25% to 30% year-over-year net sales growth, reflecting continued E-Commerce momentum and new B2B partnerships. Gross margin is expected to improve year-over-year from 61.8% in 2024, driven by supply chain optimization, cost savings initiatives, and the benefit from lower-cost inventory sales. Sales and marketing expenses are projected to increase in absolute dollars compared to $29.5 million in 2024, but decrease as a percentage of net sales compared to 29.6% in 2024, reflecting targeted brand investment and greater marketing efficiency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir
- Niagen CFO Pamir says ‘very much focused’ on profitability
- Niagen growing fast, financial health a priority, CFO tells The Fly
- Niagen CFO expects Parkinson’s trial results in early 2026
- Niagen Bioscience CFO says ‘very conservative’ in how business run